Neurofibromatosis type 2 (NF2) is a rare genetic condition that causes noncancerous tumors to grow along nerves in the brain and spinal cord. It affects roughly 1 in 33,000 people worldwide. The hallmark of NF2 is the development of tumors on both hearing nerves, a pattern almost never seen in any other condition, which typically leads to progressive hearing loss starting in the teens or early twenties.
What Causes NF2
NF2 is caused by mutations in the NF2 gene on chromosome 22. This gene normally produces a protein called merlin, which acts as a brake on cell growth. Merlin is especially active in Schwann cells, the specialized cells that wrap around and insulate nerves throughout the body. It keeps these cells from multiplying too quickly by regulating signals related to cell growth, shape, and adhesion.
Most NF2 mutations produce a shortened, nonfunctional version of merlin. Without that growth brake, Schwann cells and other nervous system cells divide unchecked, forming tumors. The condition follows an autosomal dominant inheritance pattern, meaning a single copy of the mutated gene from either parent is enough to cause it. About half of people with NF2 inherited the mutation; the other half developed a new, spontaneous mutation with no family history.
Bilateral Vestibular Schwannomas
The defining feature of NF2 is the growth of schwannomas on both vestibular nerves, which carry balance and hearing signals from the inner ear to the brain. These tumors are sometimes still called “acoustic neuromas,” though they actually originate on the vestibular portion of the nerve. Having them on both sides is so characteristic of NF2 that it is one of the primary criteria for diagnosis.
Symptoms usually begin in the teens or early adulthood. Gradual hearing loss in one or both ears is often the first sign, sometimes accompanied by ringing in the ears (tinnitus) or a sense of imbalance. As the tumors grow, they can press on nearby structures, potentially affecting nerves responsible for swallowing, speech, facial movement, and facial sensation. The rate of growth varies considerably from person to person.
Other Tumors in NF2
NF2 is not limited to the hearing nerves. An estimated 50 to 75% of people with NF2 develop meningiomas, tumors that grow in the membranes surrounding the brain and spinal cord. These are typically slow-growing but can cause headaches, seizures, or neurological symptoms depending on their location and size. Around 30% of patients also develop ependymomas, tumors that arise from cells lining the fluid-filled spaces inside the spinal cord. Spinal tumors can cause pain, weakness, or numbness in the limbs.
The total number and aggressiveness of these additional tumors varies widely. Some people have only the vestibular schwannomas and a mild course, while others develop dozens of tumors across the brain and spine over their lifetime.
Eye Problems as an Early Clue
Eye abnormalities are common in NF2 and can sometimes appear before other symptoms, making them useful for early detection. In one study, 67% of NF2 patients had lens opacities, most commonly a specific type of cataract that forms at the back of the lens (posterior subcapsular cataract). About 22% had small, benign growths on the retina called retinal hamartomas.
These cataracts are unusual because they develop at a young age, often in childhood or adolescence, well before cataracts would normally appear. A plaque-like posterior cataract or cortical cataract appearing before age 30 in someone with a family history of NF2 is considered a strong diagnostic clue. Eye exams are one of the tools used to screen at-risk family members, particularly children of an affected parent.
How NF2 Is Diagnosed
Diagnosis relies on a combination of clinical findings and genetic testing. The most straightforward path is the presence of bilateral vestibular schwannomas on MRI, which is essentially unique to NF2. When bilateral schwannomas are not yet present, doctors look for combinations of other features: a family history of NF2 plus a unilateral schwannoma, meningiomas, cataracts, or other nerve tumors.
Genetic testing for NF2 mutations has become increasingly important. Updated international diagnostic criteria now incorporate molecular data to differentiate NF2 from a related condition called schwannomatosis, which also causes nerve sheath tumors but follows a different genetic pathway. The criteria also account for mosaic forms, where the mutation is present in only some of the body’s cells, which can produce milder or more localized symptoms.
Treatment and Hearing Rehabilitation
There is no cure for NF2. Treatment focuses on managing individual tumors and preserving function for as long as possible. Many tumors grow slowly enough that careful monitoring with regular MRI scans is the first approach, with intervention reserved for tumors that are growing, pressing on critical structures, or causing worsening symptoms.
Surgery to remove vestibular schwannomas is sometimes necessary but carries significant risks, including damage to the hearing and facial nerves. The decision of when and whether to operate is one of the most consequential in NF2 care, and it depends on tumor size, rate of growth, and the patient’s remaining hearing.
A medication that blocks the growth of blood vessels feeding tumors has shown promise in shrinking vestibular schwannomas or stabilizing hearing in some NF2 patients. It is given intravenously every three weeks and is typically used when surgery is too risky or when hearing is declining rapidly. Not everyone responds, and the tumors can resume growing after treatment stops.
When hearing is lost, two types of implants can help. Cochlear implants, which stimulate the hearing nerve directly, work well for NF2 patients whose hearing nerve is still intact. In one long-term study, four of seven NF2 patients who received cochlear implants achieved the ability to understand speech without lip-reading, and all seven used their implants regularly. When the hearing nerve is damaged or removed during tumor surgery, an auditory brainstem implant can bypass the nerve entirely and stimulate the brain’s hearing centers directly, though outcomes with this device are more variable.
Long-Term Outlook
NF2 is a serious, lifelong condition, but outcomes depend heavily on when symptoms first appear and how quickly tumors grow. In a large survival analysis, five-year survival after diagnosis was 85%, ten-year survival was 67%, and twenty-year survival was 38%. Those numbers improve significantly for people whose symptoms start later in life. Patients whose first symptoms appeared at age 25 or older had a twenty-year survival rate of 62%, compared to 28% for those with earlier onset.
Tumor size at diagnosis also matters. Patients whose vestibular schwannomas were smaller than 2 centimeters at the time of diagnosis had notably better survival outcomes. Sex, the presence of skin abnormalities, and even the total number of additional brain or spinal tumors did not independently affect survival in the same analysis, reinforcing that the behavior of the vestibular schwannomas themselves is the strongest predictor of long-term prognosis.
Because NF2 requires ongoing monitoring and often multiple interventions over a lifetime, care at a specialized center with experience in the condition can make a meaningful difference in preserving neurological function and quality of life.